Funding Details
- Awarder
- Inbox
- Date Award
- May 16, 2025
- Vertical
- Biopharmaceuticals
- Funding URL
- View Funding Page
Company Info
- Traction
- Completed Phase II and Phase III clinical trials for SD-101 (Zorblisa™).
- Company Description
- Paradigm Therapeutics is a privately held, clinical-stage pharmaceutical company focused on developing innovative therapies to address critical medical needs in the treatment of rare diseases, specifically Epidermolysis Bullosa (EB). Its leading therapy, SD-101 (Zorblisa™), is a topical cream that has completed Phase II and Phase III clinical trials and aims to improve the severe skin effects seen in patients across all EB subtypes.
- Market
- Epidermolysis Bullosa (EB) treatment
- Location
-
Mt Pleasant,
South Carolina,
USA
- Coinvestors
- Eshelman Ventures, LLC
Links